These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8801747)

  • 1. [Treatment of distant iodine-negative metastases of thyroid cancer with 32P].
    Drozdovskiĭ BI; Proshin VV
    Vopr Onkol; 1996; 42(3):71-2. PubMed ID: 8801747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term results of iodine radioisotope therapy for lung metastasis of thyroid cancer].
    Tsyb AF; Drozdovskiĭ BI; Proshin VV
    Vopr Onkol; 1996; 42(3):73-5. PubMed ID: 8801748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of distant metastases of thyroid cancer using 131I].
    Drozdovskiĭ BIa; Proshin VV
    Med Radiol (Mosk); 1986 Jul; 31(7):18-20. PubMed ID: 3736381
    [No Abstract]   [Full Text] [Related]  

  • 4. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
    Haq M; Harmer C
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic therapy with radioiodine of differentiated thyroid tumor].
    Bestagno M; Campagnari G
    Minerva Med; 1986 Nov; 77(44):2113-6. PubMed ID: 3785727
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome.
    Hindié E; Zanotti-Fregonara P; Keller I; Duron F; Devaux JY; Calzada-Nocaudie M; Sarfati E; Moretti JL; Bouchard P; Toubert ME
    Endocr Relat Cancer; 2007 Sep; 14(3):799-807. PubMed ID: 17914109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-iodine-absorbing metastasis of differentiated thyroid cancer--therapeutic probe with 13-cis retinoic acid].
    Kaniewski M; Czetwertyńska M; Godlewska P; Drac-Kaniewska J
    Wiad Lek; 2001; 54 Suppl 1():297-300. PubMed ID: 12182038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 131I dosimetry and thyroid stunning.
    Gerard SK; Park HM
    J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
    [No Abstract]   [Full Text] [Related]  

  • 12. Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus (32P).
    Ariel IM; Hassouna H
    Int Surg; 1985; 70(1):63-6. PubMed ID: 4019087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radiation therapy of remote metastases from thyroid cancer].
    Kiseleva ES; Falileeva EP
    Med Radiol (Mosk); 1971 Feb; 16(2):27-37. PubMed ID: 5173489
    [No Abstract]   [Full Text] [Related]  

  • 14. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group.
    La Quaglia MP; Black T; Holcomb GW; Sklar C; Azizkhan RG; Haase GM; Newman KD
    J Pediatr Surg; 2000 Jun; 35(6):955-9; discussion 960. PubMed ID: 10873043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hurthle cell neoplasm of the thyroid gland.
    Ahmed M; Bin Yousef H; Greer W; Faraz H; Al Sobhi S; Al Zahrani A; Raef H; Al Ghamdi A; Al Kadhi Y; Al Dayel F
    ANZ J Surg; 2008 Mar; 78(3):139-43. PubMed ID: 18269475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma.
    Potsaid MS; Irwin RJ; Castronovo FP; Prout GR; Harvey WJ; Francis MD; Tofe AJ; Zamenhof RG
    J Nucl Med; 1978 Jan; 19(1):98-104. PubMed ID: 413889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined treatment of thyroid cancer metastases to the lungs in children and young people].
    Kiseleva ES; Skorobogatov NM; Zvekotkina LS; Voronetskiĭ IB
    Med Radiol (Mosk); 1987 Mar; 32(3):7-10. PubMed ID: 3561214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
    Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.